Citi analyst Samantha Semenkow downgraded Amicus (FOLD) to Neutral from Buy with a price target of $14.50, down from $17, after BioMarin BMRN) announced it will acquire Amicus for $4.8B or $14.50 per share. Citi sees low potential of another bidder emerging.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential